HIV合并心衰患者使用蛋白酶抑制剂的心血管结局
该单中心回顾性研究纳入2011年因心衰住院的394例接受抗逆转录病毒治疗的HIV感染者,按蛋白酶抑制剂(PI)与非PI方案分组。PI组高脂血症、糖尿病、冠心病比例更高,肺动脉收缩压更高,左室射血分数更低;随访中PI使用与心血管死亡和30天心衰再入院增加相关。
要点
- HIV合并心衰患者中,PI方案与更差的心血管危险因素和心脏结构功能相关。
- PI使用与心血管死亡风险约2倍增加相关,并与30天心衰再入院率升高相关。
- PI组心血管死亡预测因素包括PI使用、冠心病、肺动脉收缩压和免疫抑制。
核心结论
- 在HIV合并心衰患者中,基于PI的方案与血脂异常、糖尿病、冠心病、较低左室射血分数和较高肺动脉收缩压相关。
- 随访中接受PI的HIV合并心衰患者心血管死亡和30天心衰再入院增加。
研究设计与样本
- 回顾性单中心研究,纳入2011年因心衰住院的394例接受抗逆转录病毒治疗的HIV感染者,按PI与非PI方案分层。
- 共394例,47%女性,平均年龄60±9.5岁,CD4计数292±206 cells/mm3;145例(37%)使用PI,249例(63%)使用非PI方案。
- 所有基于PI的抗逆转录病毒治疗均包含增强剂量利托那韦。
- 主要结局为心血管死亡,次要结局为30天心衰再入院率。
主要发现
- PI组高脂血症、糖尿病和冠心病发生率更高,肺动脉收缩压更高,左室射血分数更低。
- PI使用与心血管死亡增加相关(35% vs. 17%;p < 0.001)。
- PI使用与30天心衰再入院增加相关(68% vs. 34%;p < 0.001),该效应见于所有心衰类型。
- 心血管死亡的预测因素包括PI使用、冠心病、肺动脉收缩压和免疫抑制。
- 总体上,PI与心血管死亡风险约2倍增加相关。
临床怎么用
- 对HIV合并心衰患者评估抗逆转录病毒方案时,应关注PI使用与心血管死亡及心衰再入院风险的关联。
- PI组患者需更积极管理血脂异常、糖尿病和冠心病等合并症。
- 对使用PI的HIV合并心衰患者,应加强心衰随访和再入院预防。
局限性
- 为回顾性单中心研究,可能存在混杂和选择偏倚。
- 原文未报告多变量校正后的效应估计值及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Incident heart failure (HF) is increased in persons with human immunodeficiency virus (PHIV). Protease inhibitors (PIs) are associated with adverse cardiac remodeling and vascular events; however, there are no data on the use of PIs in PHIV with HF. OBJECTIVES: This study sought to compare characteristics, cardiac structure, and outcomes in PHIV with HF who were receiving PI-based versus non-PI (NPI) therapy. METHODS: This was a retrospective single-center study of all 394 antiretroviral therapy-treated PHIV who were hospitalized with HF in 2011, stratified by PI and NPI. The primary outcome was cardiovascular (CV) mortality, and the secondary outcome was 30-day HF readmission rate. RESULTS: Of the 394 PHIV with HF (47% female, mean age 60 ± 9.5 years, CD4 count 292 ± 206 cells/mm3), 145 (37%) were prescribed a PI, whereas 249 (63%) were prescribed NPI regimens. All PI-based antiretroviral therapy contained boosted-dose ritonavir. PHIV who were receiving a PI had higher rates of hyperlipidemia, diabetes mellitus, and coronary artery disease (CAD); higher pulmonary artery systolic pressure (PASP); and lower left ventricular ejection fraction. In follow-up, PI use was associated with increased CV mortality (35% vs. 17%; p < 0.001) and 30-day HF readmission (68% vs. 34%; p < 0.001), effects seen in all HF types. Predictors of CV mortality included PI use, CAD, PASP, and immunosuppression. Overall, PIs were associated with a 2-fold increased risk of CV mortality. CONCLUSIONS: PI-based regimens in PHIV with HF are associated with dyslipidemia, diabetes, CAD, a lower left ventricular ejection fraction, and a higher PASP. In follow-up, PHIV with HF who are receiving a PI have increased CV mortality and 30-day HF readmission.
引用
- Alvi RM, Neilan AM, Tariq N, et al. Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure. J Am Coll Cardiol. 2018. PMID: 30049313. doi:10.1016/j.jacc.2018.04.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。